Tumor Genomic Profiling denied as not FDA-approved for this use by Avalon Healthcare Solutions?
Off-label use is widespread in medicine. If the literature and a recognised specialty-society guideline support the use, plans frequently approve on appeal — especially for cancer, cardiology, and rare disease.
US health-plan appeal rights
Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules
Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.
What Avalon Healthcare Solutions typically requires
Avalon manages genetic/molecular testing UM for many BCBS plans. Tumor profiling per NCCN biomarker recommendations.
What works in the appeal
Confirm Avalon network status — reroute to in-network lab if denial is purely contractual. NCCN biomarker testing recommendations require panel-based testing (NSCLC: EGFR/ALK/ROS1/BRAF/KRAS/MET/RET/NTRK/ERBB2/PD-L1). ACOG #226 (2020) — cfDNA offered to all pregnancies.
The Avalon Healthcare Solutions angle on Tumor Genomic Profiling
## Why Avalon Healthcare Solutions Denied Tumor Genomic Profiling as "Not FDA-Approved" — and How to Appeal
A "not FDA-approved" denial for tumor genomic profiling (CGP) typically reflects either a misapplication of regulatory terminology or a policy that applies a stricter standard than FDA approval for laboratory-developed tests. The FDA regulatory framework for diagnostic tests is more complex than for drugs: some CGP tests are FDA-approved companion diagnostics or have received de novo authorization; others are laboratory-developed tests (LDTs) operating under CLIA certification, which is a different regulatory pathway. Avalon may be applying a policy that requires full FDA approval/clearance when the ordered test is a CLIA-certified LDT — or the denial may simply reflect an incorrect factual determination about a test that does have FDA authorization.
## Understanding the Regulatory Landscape
If the ordered test is an FDA-approved or cleared platform (for example, an approved companion diagnostic for a specific tumor type), that is directly rebuttable with documentation from FDA's database. If the ordered test is a laboratory-developed test (LDT) under CLIA certification rather than FDA approval, the appeal argument shifts: LDTs are a recognized and clinically standard testing modality in oncology, and requiring FDA approval for all genomic tests would effectively exclude most CGP tests used in academic medical centers and major cancer programs. Guideline bodies such as NCCN do not restrict their test recommendations to FDA-approved platforms only.
## Federal Appeal Framework
ACA Section 2719 guarantees internal appeal rights and access to independent external review for non-grandfathered plans. ERISA Section 503 governs employer plans. The external review window opens after a final internal denial and is generally approximately four months. Expedited review is available for urgent oncology situations — request it explicitly.
## What to Gather Before You Appeal
- Test regulatory status documentation. Contact the ordering laboratory and ask them to confirm in writing: (a) whether the test is FDA-approved/cleared (and if so, provide the FDA authorization number and indication); or (b) if it is an LDT, confirm CLIA certification status and the laboratory's CAP accreditation.
- Avalon's clinical coverage policy. Download the specific policy Avalon applied. Identify the exact language about regulatory requirements and what standards would satisfy them.
- Treating oncologist's medical-necessity and regulatory letter. The oncologist should explain: (a) the FDA or CLIA regulatory status of the ordered test; (b) that this test is used as standard of care at major cancer centers; and (c) that the applicable guideline body (e.g., NCCN) recommends CGP for this indication without limiting the recommendation to FDA-approved platforms only.
- Diagnosis and clinical context. Confirm cancer type, stage, and clinical rationale.
## Criteria-Mapping Structure
| Avalon's denial claim | Rebuttal | Document | |---|---|---| | Test lacks FDA approval | FDA authorization (if applicable) OR CLIA/CAP status | Lab letter + FDA database | | Plan requires FDA approval standard | Policy does not exclude CLIA-certified LDTs | Policy text + oncologist letter | | Test not recognized as standard | NCCN endorses CGP for this indication | Oncologist letter |
## Practical Advice
If Avalon's policy genuinely restricts coverage to FDA-approved tests only, and the ordered test is an LDT, the external review argument is that this restriction is inconsistent with accepted oncology standards. External reviewers are specialists who apply clinical standards, not just plan policy language. Request that your external reviewer be a board-certified oncologist.
Next steps
- Find the date on the denial letter — your appeal window starts there.
- Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
- Request the insurer's claim file in writing — they must provide it.
- Submit your appeal in writing with new clinical evidence and a physician statement.
Get the letter drafted
DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.
Start my appeal — $30 with code SEO25 →